170 related articles for article (PubMed ID: 36583542)
1. Janus kinase inhibitors alter NK cell phenotypes and inhibit their antitumour capacity.
Meudec L; Richebé P; Pascaud J; Mariette X; Nocturne G
Rheumatology (Oxford); 2023 Aug; 62(8):2855-2863. PubMed ID: 36583542
[TBL] [Abstract][Full Text] [Related]
2. Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies.
Gialouri CG; Moustafa S; Thomas K; Hadziyannis E; Vassilopoulos D
Rheumatol Int; 2023 Mar; 43(3):421-435. PubMed ID: 36635577
[TBL] [Abstract][Full Text] [Related]
3. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research.
Kerschbaumer A; Smolen JS; Nash P; Doerner T; Dougados M; Fleischmann R; Geissler K; McInnes IB; Takeuchi T; Trauner M; Winthrop K; de Wit M; Boehncke WH; Falzon L; van der Heijde D
RMD Open; 2020 Nov; 6(3):. PubMed ID: 33188136
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
[TBL] [Abstract][Full Text] [Related]
5. JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells.
Fujita Y; Matsuoka N; Temmoku J; Furuya-Yashiro M; Asano T; Sato S; Matsumoto H; Watanabe H; Kozuru H; Yatsuhashi H; Kawakami A; Migita K
BMC Immunol; 2020 Jun; 21(1):35. PubMed ID: 32539713
[TBL] [Abstract][Full Text] [Related]
6. State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis.
El Jammal T; Sève P; Gerfaud-Valentin M; Jamilloux Y
Expert Opin Pharmacother; 2021 Feb; 22(2):205-218. PubMed ID: 32967471
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of different Janus kinase inhibitors combined with methotrexate for the treatment of rheumatoid arthritis: a single-center randomized trial.
Liao X; Huo W; Zeng W; Qin F; Dong F; Wei W; Lei L
Adv Rheumatol; 2023 Oct; 63(1):50. PubMed ID: 37845778
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.
Miyazaki Y; Nakano K; Nakayamada S; Kubo S; Inoue Y; Fujino Y; Tanaka Y
Ann Rheum Dis; 2021 Sep; 80(9):1130-1136. PubMed ID: 33827788
[TBL] [Abstract][Full Text] [Related]
9. [Role of janus kinase inhibitors in the treatment of rheumatic diseases].
Krüger K
Internist (Berl); 2019 Nov; 60(11):1215-1220. PubMed ID: 31486859
[TBL] [Abstract][Full Text] [Related]
10. Development of a Janus Kinase Inhibitor Prodrug for the Treatment of Rheumatoid Arthritis.
Wei X; Wu J; Zhao G; Galdamez J; Lele SM; Wang X; Liu Y; Soni DM; Purdue PE; Mikuls TR; Goldring SR; Wang D
Mol Pharm; 2018 Aug; 15(8):3456-3467. PubMed ID: 29966420
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of Janus Kinase inhibitor selectivity.
Choy EH
Rheumatology (Oxford); 2019 Jun; 58(6):953-962. PubMed ID: 30508136
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of Patients Treated with JAK Inhibitors in Rheumatoid Arthritis before versus after VTE Risk Warnings.
Philippoteaux C; Deprez V; Nottez A; Cailliau E; Houvenagel E; Deprez X; Philippe P; Pascart T; Flipo RM; Goëb V; Letarouilly JG
J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36615007
[TBL] [Abstract][Full Text] [Related]
13. JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future.
Angelini J; Talotta R; Roncato R; Fornasier G; Barbiero G; Dal Cin L; Brancati S; Scaglione F
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32635659
[TBL] [Abstract][Full Text] [Related]
14. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA
Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Retention Rate of Tofacitinib in Rheumatoid Arthritis: An Italian Multicenter Retrospective Cohort Study.
Paroli M; Becciolini A; Bravi E; Andracco R; Nucera V; Parisi S; Ometto F; Lumetti F; Farina A; Del Medico P; Colina M; Lo Gullo A; Ravagnani V; Scolieri P; Larosa M; Priora M; Visalli E; Addimanda O; Vitetta R; Volpe A; Bezzi A; Girelli F; Molica Colella AB; Caccavale R; Di Donato E; Adorni G; Santilli D; Lucchini G; Arrigoni E; Platè I; Mansueto N; Ianniello A; Fusaro E; Ditto MC; Bruzzese V; Camellino D; Bianchi G; Serale F; Foti R; Amato G; De Lucia F; Dal Bosco Y; Foti R; Reta M; Fiorenza A; Rovera G; Marchetta A; Focherini MC; Mascella F; Bernardi S; Sandri G; Giuggioli D; Salvarani C; Franchina V; Molica Colella F; Ferrero G; Ariani A
Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629770
[No Abstract] [Full Text] [Related]
16. Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events.
Atzeni F; Popa CD; Nucera V; Nurmohamed MT
Expert Rev Clin Immunol; 2022 Mar; 18(3):233-244. PubMed ID: 35129033
[TBL] [Abstract][Full Text] [Related]
17. Effect of Janus kinase inhibitors on T cell responses to herpes zoster in rheumatoid arthritis patients.
Lee JY; Kim SH; Lee SH; Kim HR; Min HK
Clin Exp Rheumatol; 2023 May; 41(5):1077-1087. PubMed ID: 36062760
[TBL] [Abstract][Full Text] [Related]
18. Stimulatory Effect of Tofacitinib on Bone Marrow Adipocytes Differentiation.
Letarouilly JG; Paccou J; Badr S; Chauveau C; Broux O; Clabaut A
Front Endocrinol (Lausanne); 2022; 13():881699. PubMed ID: 35873000
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: A systematic review and meta-analysis.
Liu L; Yan YD; Shi FH; Lin HW; Gu ZC; Li J
Front Immunol; 2022; 13():977265. PubMed ID: 36248913
[TBL] [Abstract][Full Text] [Related]
20. Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.
Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Onishi A; Jinno S; Hara R; Son Y; Amuro H; Takeuchi T; Yoshikawa A; Katayama M; Yamamoto K; Okita Y; Hirao M; Etani Y; Kumanogoh A; Okada S; Nakata K
Sci Rep; 2022 Jan; 12(1):134. PubMed ID: 34997059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]